INNOVATIVE THERAPIES BASED ON A NEXT-GENERATION DRUG DELIVERY PLATFORM

R&D

Anticancer Drug/Personalized Anticancer Drug/Osteoarthritis/COPD/Neurodegenerative Diseases

COPD

  • 01
    Chronic Obstructive
    Pulmonary Disease
    (COPD)
    COPD is a chronic life-threatening lung disease that causes obstructed airflow from the lungs. The most common forms of COPD are chronic bronchitis and emphysema, as well as refractory (non-reversible) asthma.
    According to research and consulting firm GlobalData, "The chronic obstructive pulmonary disease (COPD) space across the eight major markets... is set to rise from $9.9 billion in 2015 to around $14.1 billion by 2025, representing a compound annual growth rate of 3.7%."
    Despite the increasing number of drugs available on the market, COPD remains an incurable disease.
  • 02
    Therapeutics
    Development
    The regenerative effects of MSCDVs were observed in the damaged lungs of the animal model of COPD. This study was conducted in collaboration with Seoul Asan Medical Center.
    Intratracheal administration presents a higher regenerative effect in lung cells at a lower dosage compared to intravenous injections.
    Based on these promising results, an Investigational New Drug (IND) application for COPD will be submitted in 2022.